Skip to main content
OpenTrials
Completed

NCT Number: NCT01428739

Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer

Correlation between MRS and Tumor Response Therapy in Breast Cancer.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada

About this study

Correlation between MRS (Magnetic Resonance Spectroscopy and Tumor Response to Radiation in Breast Cancer

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologically confirmed diagnosed Breast cancer
  • Patient is 18 years or older
  • Karnofsky performance score > 70
  • No previously irradiated or recurrent breast cancer
  • No contraindication to MRS/MRI
  • Signed informed consent.

Treatment and study plan

MRS

Device

Procedure

Other names: Philips 3 Tesla MRI Scanner

Primary outcomes

  1. MRS Correlation with Treatment Response

    Time frame: Up to One Year

    measuring choline, water and fat levels by proton magnetic resonance spectroscopy in breast tumors in response to treatment

Secondary outcomes

  1. Correlation with Tumor Stage

    Time frame: Up to One year

Sponsors and collaborators

Lead sponsor

AHS Cancer Control Alberta

Other

Registry information

Important dates

Study start
2007
Primary completion
2014
Study completion
2014
First posted
Sep 5, 2011
Registry last updated
Jan 25, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.